CMV disease remains a major infectious complication after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate the relationship between CMV antigenemia, treatment with ganciclovir (GCV), and outcome, we retrospectively analyzed 241 consecutive patients at risk for CMV infection who underwent allogeneic HSCT. Antigenemia-guided pre-emptive strategy with GCV was used for all patients. CMV antigenemia developed in 169 patients (70.1%), and CMV disease in 18 patients (7.5%). Multivariate analysis showed that acute GVHD (grades II-IV) was the only risk factor for developing antigenemia, and acute GVHD and advanced age for CMV disease. GCV use, as well as acute GVHD and advanced age, significantly increased the risk for bacterial and fungal infection after engraftment. Those who developed CMV antigenemia had a poorer outcome than those who did not (log-rank, P ¼ 0.0269), although the development of CMV disease worsened the outcome with only borderline significance (log-rank, P ¼ 0.0526). In conclusion, detection of antigenemia proved to be a poor prognostic factor for HSCT patients, which may be attributed to a combination of factors, including CMV disease itself, the effect of treatment, and a host status that allows for reactivation of CMV. Optimal pre-emptive strategy needs to be determined.
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CMV disease remains a major infectious complication after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate the relationship between CMV antigenemia, treatment with ganciclovir (GCV), and outcome, we retrospectively analyzed 241 consecutive patients at risk for CMV infection who underwent allogeneic HSCT. Antigenemia-guided pre-emptive strategy with GCV was used for all patients. CMV antigenemia developed in 169 patients (70.1%), and CMV disease in 18 patients (7.5%). Multivariate analysis showed that acute GVHD (grades II-IV) was the only risk factor for developing antigenemia, and acute GVHD and advanced age for CMV disease. GCV use, as well as acute GVHD and advanced age, significantly increased the risk for bacterial and fungal infection after engraftment. Those who developed CMV antigenemia had a poorer outcome than those who did not (log-rank, P ¼ 0.0269), although the development of CMV disease worsened the outcome with only borderline significance (log-rank, P ¼ 0.0526). In conclusion, detection of antigenemia proved to be a poor prognostic factor for HSCT patients, which may be attributed to a combination of factors, including CMV disease itself, the effect of treatment, and a host status that allows for reactivation of CMV. Optimal pre-emptive strategy needs to be determined. Bone Marrow Transplantation (2003) 32, 801-807. doi:10.1038/sj.bmt.1704232 Keywords: cytomegalovirus; antigenemia; pre-emptive therapy; ganciclovir; hematopoietic stem cell transplantation Despite recent advances in the development of antiviral agents and diagnostic techniques, CMV disease remains a common cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Preemptive therapy with ganciclovir (GCV) has been widely adopted combined with use of the antigenemia assay or PCR to monitor CMV reactivation. With this approach, patients at risk are placed under surveillance for subclinical CMV infection during the critical period, and GCV is administered pre-emptively in order to prevent the development of established CMV disease. Two major problems have emerged as a result of early intervention with GCV: late CMV disease and secondary infection with bacteria and fungus. Excessive suppression of CMV replication delays recovery of CMV-specific T-cell immunity, 1 so that viral reactivation occasionally occurs after discontinuation of antiviral therapy. [2] [3] [4] Additionally, GCV use is associated with bone marrow toxicity, 5 and neutropenia may increase the risk for bacterial and fungal infection.
In this multicenter, retrospective study, we analyzed the records of 241 consecutive patients at risk for CMV infection who underwent allogeneic HSCT, in order to investigate the relationship among antigenemia, preemptive therapy with GCV, and outcome.
Patients and methods

Patient population
Adult patients who underwent allogeneic HSCT in the Nagoya BMT Group between July 1997 and December 2000 were eligible for inclusion. Of the 272 patients whose data were available, nine were excluded because both the donor and the recipient had negative pretransplant serology for CMV, and 22 were excluded because of death within 28 days post transplant. The data for the remaining 241 patients were all included in the analysis. Matching of donors and recipients was based on serologic typing of HLA-A, -B, and -DR antigens, and HLA-DRB1 DNA typing was performed when donors and recipients were unrelated. Donors other than HLA-identical siblings were defined as alternative donors.
Pre-emptive therapy with ganciclovir
Patients were generally monitored for CMV antigenemia weekly from engraftment until approximately day 100. In most cases, GCV was initiated at an induction dose of 5 mg/kg intravenously every 12 h when any positive results were obtained. After antigenemia had been eliminated, GCV was either discontinued immediately or continued for a short time at a maintenance dose, in accordance with the institutional strategy.
CMV antigenemia assay
The CMV antigenemia assay was performed as described elsewhere. 6 Five processes were included in the assay: (1) isolation of the polymorphonuclear leukocytes (PMNLs) by dextran sedimentation, (2) fixing of PMNLs on slides by means of cytospin, (3) acetone fixation, (4) immunostaining with monoclonal antibodies, and (5) quantification based on the results of microscopic examination. The monoclonal antibodies were either C10/C11 (Biotest, Dreieich, Germany), which targets the lower matrix protein pp65, or HRP-C7 (Teijin, Tokyo, Japan), a peroxidase-conjugated antibody targeting immediate-early antigens. For the preparation of one slide, 150 000 cells were cytospun. The results are reported as the number of antigen-positive cells per slide. In C10/C11 assay, two slides per sample were stained, and the mean value was used for the subsequent analysis.
Definition of CMV infection and disease
Diagnosis of CMV infection and disease was based on previously described criteria. 7 In brief, CMV infection was defined as the isolation of virus or detection of viral protein or nucleic acid in any body fluid or tissue specimen. CMV disease was defined by the presence of clinical signs and/or symptoms of end-organ disease combined with the detection of CMV infection in a biopsy specimen or bronchoalveolar lavage fluid in case of pneumonia. CMV disease occurring after day 100 was defined as late CMV disease. The CMV antigenemia test was considered positive if at least one positive-stained cell was detected on the slides.
Statistical analysis
The following variables were analyzed by univariate analysis to determine risk factors for CMV antigenemia and disease: age (as a continuous variable), sex (male or female), donor type (HLA-identical sibling or alternative donor), conditioning regimen (TBI-containing regimen or non-TBI regimen), acute GVHD (grades 0-I or II-IV), and chronic GVHD (present or absent). GCV use was added to evaluate risk factors for bacterial and fungal infection. The initial exploratory analyses employed the univariate Cox proportional hazards regression analysis for age, and the w 2 tests or Fisher's exact tests for other categorical variables. The factors with P-values less than 0.10 were included in the multivariate analysis. A Cox proportional hazards regression model was used to assess the risk, adjusting other variables. Hazard ratios were calculated in conjunction with 95% confidence intervals (95% CI). Duration between initiation of GCV and disappearance of antigenemia was compared using the Wilcoxon rank-sum test. The Kaplan-Meier analysis was performed to estimate overall survival, freedom from CMV disease, and freedom from antigenemia recurrence. The probabilities between subgroups were compared by means of the log-rank test. A P-value of 0.05 was considered to be statistically significant. Stat View 5.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Patients
Patient characteristics are shown in Table 1 . None of the patients received T-cell-depleted transplants, while antigenemia-guided pre-emptive strategy with GCV was used for all patients. Foscarnet was used in only four patients for salvage therapy.
CMV antigenemia
CMV antigenemia was documented in 169 patients (70.1%) at a median onset of 35 days (range, 15-142). A total of 51 patients (21.2%) were antigen-positive at the first test post engraftment. For those with CMV antigenemia, the median peak level was 4.0 (range, 0.5-1014). Age X40 years, male sex, and acute GVHD grades II-IV were included in a multivariate Cox model, and only acute GVHD was found to have significant influence on the development of antigenemia (hazard ratio: 1.61 (95% CI, 1.17-2.21)) ( Table 2 ). The median duration between initiation of GCV and disappearance of antigenemia was 12 days (range, 1-54). Patients with acute GVHD or those developing CMV disease required significantly longer duration of therapy than those without (P ¼ 0.0104, 0.0110, respectively).
CMV disease
A total of 18 patients (7.5%) developed 19 episodes of CMV disease at a median onset of 52 days (range, 20-245), and three died of the disease. Detailed characteristics and Pre-emptive therapy with ganciclovir and its outcome outcomes of patients developing CMV disease are shown in Table 3 . The incidence of CMV pneumonia was lower than that of gastroenteritis, but the mortality rate for the former was significantly higher than that for other diseases (P ¼ 0.0157). Based on the results of the univariate analysis, acute GVHD and age were included in the multivariate analysis, and both were confirmed to affect the incidence of CMV disease independently (hazard ratio: 2.80 (95% CI, 1.10-7.14) for acute GVHD, 1.60 (95% CI, 1.02-2.52) per decade for age) ( Table 2) . Patients with any antigenemia, more than five antigen-positive cells, and more than 10 antigen-positive cells developed CMV disease more frequently compared to those without (log-rank, P ¼ 0.0204, 0.0009, o0.0001, respectively). Four patients developed gastroenteritis despite negative antigenemia results prior to disease onset.
Bacterial and fungal infection after engraftment
A total of 42 patients (17.4%) documented bacterial and fungal infection after engraftment. Multivariate analysis showed that GCV use, as well as acute GVHD grades II-IV and age, significantly correlated with the risk for bacterial and fungal infection (Table 4 ). In all, 31 patients developed bacterial and fungal infection during or after GCV treatment, while among the patients who developed CMV disease, the incidence reached 62%.
Recurrence of CMV antigenemia
GCV was discontinued in 90 patients within 5 days after the first disappearance of antigenemia (Group A), while GCV was continued at a dose of less than 10 mg/kg/day (mostly 5 mg/kg/day) for longer than 6 days in 49 patients (Group B). The overall probability of antigenemia recurrence was 79.5% on day 100, without any significant difference between the groups (log-rank, P ¼ 0.1371). When stratified by severity of acute GVHD, no difference was found among patients with grades 0-I (log-rank, P ¼ 0.6494, Figure 1a ), but recurrence was more frequent in group A, among patients with grades II-IV (log-rank, P ¼ 0.0438, Figure 1b) .
Rising antigenemia
Occasionally, the antigenemia level increases even while an antiviral agent is being administered, and this phenomenon is known as 'rising antigenemia'. 8 In this study, rising antigenemia was defined as the observation of an increase in the antigenemia level to more than double that of the baseline after GCV 10 mg/kg/day for more than 7 days. In our subjects, 25 episodes of rising antigenemia occurred in 22 patients. All patients developed acute GVHD, and 15 patients were receiving corticosteroids. GCV was continued at the same dose in all cases. Kinetics of the antigenemia levels are shown in Figure 2 . In 22 of 25 episodes, the antigenemia level declined during the week following the development of a rising antigenemia. In the other three episodes, the peak antigenemia level was observed in week 3. Although antigenemia improved in all episodes as a result of the continuation of GCV, six episodes subsequently progressed to CMV disease.
Outcome
Patients who developed CMV antigenemia had a poorer prognosis than those who did not (log-rank, P ¼ 0.0269, Pre-emptive therapy with ganciclovir and its outcome M Yanada et al Figure 3a ). Survival analysis of these patients, after they had been divided according to whether or not more than 10 antigen-positive cells were observed, revealed a greater significance (log-rank, P ¼ 0.0021). Development of CMV disease tended to correlate with a worse outcome (log-rank, P ¼ 0.0526, Figure 3b ). For the patients who developed antigenemia, significant adverse factors for survival were antigenemia recurrence, detection of more than 10 antigen-positive cells, and development of bacterial and fungal infection (log-rank, P ¼ 0.0110, 0.0224, o0.0001, respectively).
Discussion
The incidence of CMV disease in our subjects was 7.5%, which was similar to, or less than the recently reported results of pre-emptive therapy for other groups.
2,9,10 The frequency of CMV pneumonia was low (1.7%), but was associated with a higher mortality rate. In contrast, gastroenteritis was observed frequently (5.0%) but was accompanied by a low mortality rate. In total, overall risk of death directly due to CMV disease was low. Four patients with gastroenteritis did not demonstrate positive antigenemia prior to disease onset, suggesting that CMV surveillance using the antigenemia assay might be of limited value in cases of gastroenteritis.
Several factors have been identified as risk factors for CMV infection and disease in allogeneic HSCT, including pretransplant serostatus, GVHD, transplant from an unrelated or HLA mismatched donor, the use of TBI or ATG in the conditioning regimen, T-cell-depleted transplant, and advanced age. [11] [12] [13] [14] [15] [16] [17] [18] In particular, GVHD and donor type are considered to be strong indicators, as well as pretransplant serostatus. Our study demonstrated that acute GVHD had a significant influence on CMV antigenemia and disease, but that donor type did not. These results are not discrepant, however, because the incidence and severity of acute GVHD in our study was almost identical for transplants from HLA-identical sibling donors and transplants from alternative donors (acute GVHD grades II-IV; 28.0 vs 34.9%, P ¼ 0.2542). We previously reported a lower probability of severe acute GVHD in unrelated transplants for Japanese populations than for Caucasian populations, 19, 20 which may be due to the variety of genetic backgrounds resulting from ethnics diversity in the latter. An analysis of a large population report of unrelated HSCT in Japan found that the probability of survival was equivalent or slightly better than that reported for Western populations. 21 Our study also showed that the prognosis for those who developed antigenemia was significantly poorer than was Pre-emptive therapy with ganciclovir and its outcome the prognosis for those who did not, while development of CMV disease tended to affect the outcome, but with only borderline significance. Subsequent CMV disease was not the only cause of a worse prognosis for such patients. It is our opinion that the poor outcome for patients developing antigenemia can be attributed to a combination of multiple factors, including CMV disease itself, the effect of its treatment, and host factors that allow reactivation of CMV. Among patients with antigenemia, three adverse factors for survival were identified: antigenemia recurrence, detection of more than 10 antigen-positive cells, and development of bacterial and fungal infection, all of which reflect an immunocompromised state. Although a pre-emptive strategy is becoming the treatment of choice for post HSCT CMV management, 22 the optimum duration and dosage of GCV have not been established. Continuing GCV at a maintenance dose (5 mg/ kg/day) until day 100 is a well-known method, 23, 24 but shorter therapy periods have also been tried out for the prevention of GCV-related complications.
9,10,25-27 Shortterm GCV therapy was used for the majority of our patients, and the incidence of late CMV disease was only 1.4% for patients surviving more than 100 days post transplant. Among those with acute GVHD grades 0-I, the probability of antigenemia recurrence was similar for patients whose GCV administration was discontinued immediately after antigenemia disappearance and those who received GCV at a maintenance dose. In contrast, maintenance therapy was effective for those with acute GVHD grades II-IV. These results indicate that a riskadapted pre-emptive strategy is needed, based on the severity of acute GVHD. Even with short-term pre-emptive therapy, however, the use of GCV is associated with an increased risk of bacterial and fungal infection, as reported extensively in the literature. 2, 5, 23, 24 From our study, it could not be concluded that GCV above was involved in the increased risk, and it is possible that the immunocompromised status of the host, or a direct effect of CMV made some contributions. Regardless of the mechanism, it is suggested that prolonged administration of GCV may be of clinical value for high-risk patients, but careful monitoring and management of secondary infections is required.
Nichols et al 8 reported a high incidence of rising antigenemia while patients were receiving pre-emptive therapy, which was caused by the immunosuppressed status of the host, not by resistance to antiviral agents. The incidence reported by them (39%) was substantially higher than the 13% of cases with rising antigenemina observed among the patients in our study. Notably, all patients developing rising antigenemia in our study had acute GVHD, suggesting that the immunological status of the host may be of importance. In every case, the level of antigenemia declined within 2 weeks as a result of the continuation of GCV therapy, but six out of 22 patients subsequently developed CMV disease. Such cases should antigenemia recurrence. Differences between Group A (discontinued GCV without maintenance) and Group B (discontinued GCV after maintenance) were compared separately according to the severity of acute GVHD. No difference was found among patients with grades 0-I (a, logrank, P ¼ 0.6494), but recurrence was more frequent in Group A among patients with grades II-IV (b; log-rank, P ¼ 0.0438). AG ¼ antigenemia.
therefore be treated with caution even after antigenemia has improved.
In conclusion, detection of antigenemia was found to be a poor prognostic factor for HSCT patients. Such a poor prognosis may also be attributed to multiple factors, including CMV disease itself, the effect of GCV treatment, and a host status that allows reactivation of CMV. Acute GVHD had a strong influence on the development of CMV antigenemia and disease, indicating an urgent need for the establishment of an optimum pre-emptive strategy based on the severity of acute GVHD. Patients with any sign of positive antigenemia had poorer overall survival than patients without (a; log-rank, P ¼ 0.0269). CMV disease tended to affect the outcome with borderline significance (b; log-rank, P ¼ 0.0526).
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